Skip to main content

Table 3 Association of SLC7A5 protein expression and the expression of other molecular biomarkers in the discovery and validation sets

From: The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours

SLC7A5 protein

Discovery set

Validation set

 

Number (%)

Mean

p value

Adjusted p value

Number (%)

Mean

p value

Adjusted p value

ER

 Negative

270 (25)

722.20

3.2 × 10−48

<0.0001

300 (19)

1094.70

4.6 × 10−76

<0.0001

 Positive

827 (75)

492.45

1240 (81)

692.06

PgR

 Negative

435 (41)

619.12

8.8 × 10−27

<0.0001

612 (42)

855.53

1.3 × 10−34

<0.0001

 Positive

630 (59)

473.54

853 (58)

645.09

HER2

 Negative

921 (87)

521.78

0.00004

0.0001

1337 (92)

718.53

0.001

0.002

 Positive

143 (13)

601.54

116 (8)

824.67

Triple negative

 No

896 (83)

503.50

4.5 × 10−35

<0.0001

1286 (83)

696.76

1.5 × 10−62

<0.0001

 Yes

185 (17)

722.61

225 (17)

1094.6

Basal phenotype

 No

794 (74)

510.96

6.8 × 10−13

<0.0001

N/A

 Yes

285 (26)

620.90

P53 protein

 Negative

760 (72)

499.14

4.1 × 10−13

<0.0001

N/A

 Positive

298 (28)

606.92

  1. ER oestrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor, NA not applicable
  2. p value in bold in these tables means statistically significant associations